Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity

Clinical Nuclear Medicine

Volumn 32, Issue 2, 2007, Pages 101-105

  Xiu, Yan ^a,b   Bhutani, Chirdeep ^a   Dhurairaj, Thiruvenkatasamy ^a   Yu, Jian Q ^a   Dadparvar, Simin ^a   Reddy, Swapna ^a   Kumar, Rakesh ^a   Yang, Hua ^a   Alavi, Abass ^a   Zhuang, Hongming ^a,c,d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Dual time; FDG PET; Lung nodule; Minimal activity

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HYPERMETABOLISM; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG ASPERGILLOSIS; LUNG NODULE; LUNG SARCOIDOSIS; LUNG TUBERCULOSIS; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY;

COIN LESION, PULMONARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TIME FACTORS;

EID: 33846449432     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000252457.54929.b7     Document Type: Article

References (34)

1. Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med. 1994;35:1771-1776.
2. Imdahl A, Jenkner S, Brink I, et al. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Eur J Cardiothorac Surg. 2001;20:324-329.
3. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47-59.
4. Nguyen QH, Szeto E, Mansberg R, et al. Paravertebral infection (Phlegmon) demonstrated by FDG dual-head coincidence imaging in a patient with multiple malignancies. Clin Nucl Med. 2005;30:241-243.
5. Goethals I, Smeets P, De Winter O, et al. Focally enhanced f-18 fluorodeoxyglucose (FDG) uptake in incidentally detected pulmonary embolism on PET/CT scanning. Clin Nucl Med. 2006;31:497-498.
6. Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med. 2006;31:386-390.
7. Houseni M, Chamroonrat W, Zhuang HA. A facet joint arthropathy demonstrated on FDG-PET. Clin Nucl Med. 2006;31:418-419.
8. Huang SS, Yu JQ, Chamroonrat W, et al. Achilles tendonitis detected by FDG-PET. Clin Nucl Med. 2006;31:147-148.
9. Zhuang H, Sam JW, Chacko TK, et al. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur J Nucl Med Mol Imag. 2003;30:1096-1103.
10. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993;188:487-490.
11. Al-Sugair A, Coleman RE. Applications of PET in lung cancer. Semin Nucl Med. 1998;28:303-319.
12. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-1348.
13. Conrad GR, Sinha P. Narrow time-window dual-point F-18-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun. 2003;24:1129-1137.
14. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point F-18-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
15. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-D- glucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21:3651-3658.
16. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using 'quantitative' parameters of FDG PET images. Clin Nucl Med. 1996;21:941-949.
17. Acton PD, Zhuang H, Alavi A. Quantification in PET. Radiol Clin North Am. 2004;42:1055.
18. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355-359.
19. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med. 1993;34:1-6.
20. Minn H, Leskinen-Kallio S, Lindholm P, et al. [18F]fluorodeoxyglucose uptake in tumors: kinetic vs steady-state methods with reference to plasma insulin. J Comput Assist Tomogr. 1993;17:115-123.
21. Boerner AR, Weckesser M, Herzog H, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26:226-230.
22. Hickeson M, Yun MJ, Matthies A, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging. 2002;29:1639-1647.
23. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35:1308-1312.
24. Sahlmann CO, Siefker U, Lehmann K, et al. Dual time point 2- F-18 fluoro-2′-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun. 2004;25:819-823.
25. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
26. Suzuki S, Toyota T, Suzuki H, et al. Partial purification from human mononuclear cells and placental plasma membranes of an insulin mediator which stimulates pyruvate dehydrogenase and suppresses glucose-6-phosphatase. Arch Biochem Biophys. 1984;235:418-426.
27. Gallagher BM, Fowler JS, Gutterson NI, et al. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978;19:1154-1161.
28. Nelson CA, Wang JQ, Leav I, et al. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol. 1996;23:533-541.
29. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
30. Matthies A, Hickeson M, Cuchiara A, et al. Dual time point F-18-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871-875.
31. Nakamoto Y, Higashi T, Sakahara H, et al. Delayed (18)F-fluoro-2-deoxy-D- glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547-2554.
32. Demura Y, Tsuchida T, Ishizaki T, et al. F-18-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540-548.
33. Dobert N, Hamscho N, Menzel C, et al. Limitations of dual time point FDG-PET imaging in the evaluation of focal abdominal lesions. Nuklearmedizin. 2004;43:143-149.
34. Yen TC, Chang YC, Chan SC, et al. Are dual-phase F-18-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging. 2005;32:541-548.